We observed that a selective depletion of CD8+ T cells completely abrogated the antitumor efficacy of the Id1-PD-1 double blockade against LLC cells and restored the expected tumor growth (Id1sh/DPBS, n.s.; Id1sh/anti-PD-1, p = 0.0425) (Figure 5C,D). This evidence concerns the gene CD8A and neoplasm.